A Multicentre, Open Label, Observational 24-Week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir (Insulin Detemir) Once-Daily in Oral Antidiabetic Drug-Treated Patients With Type 2 Diabetes.

Trial Profile

A Multicentre, Open Label, Observational 24-Week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir (Insulin Detemir) Once-Daily in Oral Antidiabetic Drug-Treated Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms SOLVE
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2016 Results (n=17374) of patient subgroup analysis were published in the International Journal of Clinical Practice.
    • 28 Jun 2011 Acutal patient number (n=12,989) reported at 71st Scientific Sessions of the America Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top